Currentamerican_specialty_healthPolicy N/A

Complex lymphedema therapy (Complete Decongestive Therapy)

Customize your policy alerts

Sign up for all american_specialty_health policy alerts

Know when american_specialty_health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical coverage and clinical criteria for complex lymphedema therapy (complete decongestive therapy) for members under Cigna/ASH-administered plans, including indications, contraindications, duration/frequency, and supporting documentation requirements.

Policy Summary

Payeramerican_specialty_health

PolicyComplex lymphedema therapy (Complete Decongestive Therapy)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMay 15, 2025

Next Review DateMay 15, 2026

Key ActionDocument limb volume measurements and prior conservative management when submitting claims; include appropriate covered diagnosis and procedure codes to avoid denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2-5x/wktypical medically necessary treatment frequency

2-4 wksPhase I duration

Phase I & IIphases described

45-70%avg volume reduction

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentamerican_specialty_healthPolicy N/A

Complex lymphedema therapy (Complete Decongestive Therapy)

Customize your policy alerts

Sign up for all american_specialty_health policy alerts

Know when american_specialty_health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payeramerican_specialty_health

PolicyComplex lymphedema therapy (Complete Decongestive Therapy)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMay 15, 2025

Next Review DateMay 15, 2026

Key ActionDocument limb volume measurements and prior conservative management when submitting claims; include appropriate covered diagnosis and procedure codes to avoid denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2-5x/wktypical medically necessary treatment frequency

2-4 wksPhase I duration

Phase I & IIphases described

45-70%avg volume reduction

CPT 97016 not coveredIPC status

40 RCTsevidence base

Coverage and Medical Necessity Criteria

Medically Necessary — Covered when ALL of the following are met:

Covered when ALL of the following are met:

Documented conservative management failure: Documented failure of a reasonable course of conservative medical management that includes home exercises, limb elevation, and compression garments.

Functional impairment: The lymphedema is directly responsible for impaired functioning in the affected limb.

Prescribing provider: The complex lymphedema therapy is prescribed by or under the supervision of an appropriate healthcare provider.

Duration and Frequency — program length and visit frequency constraints

Frequency and duration: A program provided 2-5 times per week for two weeks is generally considered medically necessary; programs that extend beyond a four-week period are generally considered not medically necessary.2-5 sessions/week; typical total 2 weeks (phase I); programs >4 weeks not medically necessary

Report and document treatment schedule and clinical response; maintenance (Phase II) consists of self-management and compression garment use rather than continued intensive supervised visits.

Coverage rationale / evidence statements — guideline-based diagnosis and conservative management prerequisite referenced

Covered when supported by guideline-based diagnosis and need for conservative management:

CDT as standard care: Complete Decongestive Therapy (CDT) is recognized internationally and is suggested as the main method of conservative care for lymphedema; CDT includes manual lymphatic drainage, low-stretch multilayer bandaging/compression, exercise, and skin care.

Supported by AHRQ technology assessment, NLN position statement, and ISL consensus.

Component evidence: Compression bandaging and compression garments demonstrate the strongest evidence for clinical benefit; combined CDT programs often yield greater volume reduction than single modalities alone.

Multiple systematic reviews and trials report larger effect sizes with multimodal CDT.

Conservative-first requirement: Prior conservative management (home exercises, limb elevation, compression garments) should have been attempted and documented before initiating supervised complex lymphedema therapy.

Documentation of prior measures and response required.

Coverage considerations for CDT and adjuncts — evidence-based considerations and component-level guidance

Summary of evidence-based coverage considerations

CDT as main conservative therapy: Complete decongestive therapy (CDT) is supported as the principal conservative treatment across reviews and is considered the gold standard for lymphedema management.

Evidence quality varies; multiple systematic reviews and trials cited.

MLD and exercise components: Manual lymphatic drainage (MLD) shows benefit for pain but has inconsistent evidence for additional limb volume reduction; exercise (resistance/aerobic) is safe and improves function and quality of life without worsening lymphedema.

Some reviews find limited added volume benefit from MLD while exercise benefits function/QoL.

Adjunct therapies and devices: Adjuncts (LLLT, kinesio taping, APCDs, intermittent pneumatic compression) report mixed or low-quality evidence; some trials suggest benefit with specific protocols and devices, but overall findings are heterogeneous.

Evidence for adjuncts is protocol-dependent; high-quality RCTs are needed.

Considered Medically Necessary — alternate/related 'all of the following' criteria group

Covered when ALL of the following are met:

Criteria met for covered codes: HCPCS codes 97140 (manual therapy techniques, including manual lymphatic drainage) and S8950 (complex lymphedema therapy) are considered medically necessary when the clinical criteria and documentation requirements in this policy are met.per 15-minute unit

Submit claims with appropriate covered diagnosis and procedure codes; lack of covered codes may result in denial.

Documentation and measurement: Treatment must be supported by documented diagnosis (e.g., limb volume difference >10%), prior conservative management, and objective pre/post measurements to justify skilled supervised therapy.>10%

Document staging, measurement method, prior therapies attempted, and clinical response.

Use of a vasopneumatic (intermittent pneumatic) compression device as part of complex lymphedema therapy is explicitly considered not medically necessary. The policy lists application of vasopneumatic devices (CPT 97016) as a not‑medically‑necessary service for lymphedema therapy and states that vasopneumatic compression device use within CLT is not supported.

Claims for lymphedema treatment that include CPT 97016 may be denied as not covered when submitted for complex lymphedema therapy, consistent with the policy exclusion for vasopneumatic compression within CLT.

Low‑level laser therapy (LLLT) has been studied as an adjunct to standard lymphedema treatments but is regarded in this policy as experimental, investigational and/or unproven. Systematic reviews and updated analyses report conflicting results: some trials show short‑term benefit versus sham or no treatment, but comparisons versus active interventions are inconsistent and overall evidence quality is low.

Because optimal treatment parameters and long‑term effects remain uncertain and many trials have high or unclear risk of bias, routine coverage of LLLT for lymphedema is not supported by the current evidence base described in the policy.

Kinesio taping (KT) has mixed and limited evidence compared with standard compression bandaging. Several randomized trials and systematic reviews found no consistent superiority of KT over usual care or bandaging for limb volume reduction, and pooled analyses showed no significant difference between KT and compression.

Safety data indicate an increased risk of skin complications with KT in some studies, with reported rates of skin adverse events between 10% and 21%. For these reasons the policy advises caution in the use of KT and suggests it may only be appropriate where standard bandaging cannot be used.

Overall evidence for adjunct therapies to complete decongestive therapy (CDT) is mixed and of variable quality. Large rapid reviews and overviews of systematic reviews report many trials with 'some concerns' or 'high risk of bias', heterogeneous interventions and inconsistent outcome reporting, limiting confidence in effect estimates for modalities such as LLLT, IPC and taping.

At a policy level, this uncertainty supports restricting routine coverage of adjunct interventions unless there is clear, guideline‑based indication, documented diagnosis and staging, prior conservative management, and supporting documentation of expected benefit for the individual patient.

At the coding level, the policy explicitly identifies CPT 97016 (Application of a modality; vasopneumatic devices) as not medically necessary when billed for lymphedema therapy. Providers should not report CPT 97016 for complex lymphedema therapy seeking coverage under this policy.

Covered procedure codes for CLT (e.g., HCPCS codes described elsewhere in the policy) are considered medically necessary only when the policy’s clinical criteria and documentation requirements are met; by contrast, CPT 97016 is listed as a specific exclusion and may be denied if billed for lymphedema services.

The policy defines typical medically necessary programs as 2–5 sessions per week for two weeks (commonly totaling 2–4 weeks for Phase I). Programs that continue beyond a four‑week period are generally considered not medically necessary unless there is clear documentation meeting specific policy criteria to justify extended care.

Providers should document limb volume measurements, clinical response, and prior conservative measures when requesting or continuing CLT; routine extension of programs beyond the stated duration without supportive documentation is not supported.

Evidence for manual lymphatic drainage (MLD) as a standalone therapy is limited and inconsistent. Systematic reviews and trials show conflicting findings: some studies report minor benefits for volume, others show no additional benefit when MLD is added to other CDT components.

MLD may have a role in prevention or treatment in selected settings, but the literature does not consistently support MLD alone as an effective intervention for breast cancer–related lymphedema. The policy therefore emphasizes CDT as a multimodal approach rather than routine reliance on MLD alone.

Across reviews and trials, evidence supporting MLD and LLLT for clinically meaningful limb volume reduction is mixed and generally limited by small samples, heterogeneous treatment protocols and variable risk of bias. Some studies report short‑term reductions with LLLT or with intensive CDT, but results are not uniform across settings or compared with active controls.

Given these limitations the policy concludes there is insufficient high‑quality, consistent literature to broadly endorse MLD or LLLT as reliably effective for volume reduction in all clinical contexts; coverage decisions rely on meeting the policy’s diagnostic, staging, and documentation criteria.

For clarity at the coding and coverage level, CPT 97016 (Application of a modality; vasopneumatic devices) is reiterated as not medically necessary when provided for lymphedema therapy and may be denied if submitted for that purpose.

This coding exclusion reinforces the policy’s position that vasopneumatic/IPC devices are not supported as part of routine CLT and should not be billed using CPT 97016 for covered lymphedema therapy services.

Billing Codes, Diagnostic Thresholds, and Measurement

Considered medically necessary HCPCS/CPT codesmixedCovered

97140	Manual therapy techniques (eg, mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
S8950	Complex lymphedema therapy, each 15 minutes

Unit/time reportingmixed

per 15 minutes

Each code reported per 15-minute unit

Considered not medically necessaryCPTNot Covered

97016

Application of a modality to 1 or more areas; vasopneumatic devices

inv-17: Limb volume difference for diagnosis — commonly used diagnostic threshold

Common diagnostic threshold>10% limb volume difference between affected and unaffected limb

PurposeUsed in guidelines and consensus documents to confirm presence of clinically significant lymphedema

Documentation roleRequired in assessment and treatment decisions; supports medical necessity for CDT when reported with clinical findings

inv-18: Diagnostic limb volume threshold — numeric threshold (>10%)

Numeric threshold>10% limb volume difference

ApplicationCompare affected limb volume to contralateral (unaffected) limb during diagnostic evaluation

Prior Authorization, Documentation, and Billing Guidance

Billing Rule

Submit covered diagnosis and procedure codes

When submitting claims, include the covered diagnosis and procedure codes listed in the Coding Information section (e.g., HCPCS 97140 and S8950). Claims for services not submitted with covered code(s) under this policy will be denied as not covered.

Complex lymphedema therapy must be prescribed by or under the supervision of an appropriate healthcare provider.

Prior Authorization

No explicit prior‑auth rule — document clinical justification

The policy text does not establish specific prior authorization rules in the coverage criteria; however, clinical documentation (limb measurements, staging, prior conservative care) is emphasized to justify skilled CDT services.

Definitions and Treatment Phases

inv-42: Complex lymphedema therapy (CLT) / Complete decongestive therapy (CDT) — component definition

DefinitionA noninvasive, multi-component program (also called CDT) including skin and nail care, manual lymphatic drainage (MLD), multi-layer compression bandaging, therapeutic exercise, and patient education/maintenance

Treatment settingTypically outpatient in office or specialized lymphedema clinic; programs often progress to home-based self-management

PhasesTypically delivered in two phases — an intensive treatment phase (Phase I) followed by a maintenance/self-management phase (Phase II)

inv-43: Lymphedema stages — staging definitions (0-III)

Stage 0Latent/subclinical — impaired lymph circulation without visible swelling; symptoms may be subtle (eg, heaviness)

Stage I

Clinical Background

Lymphedema is a condition of excess protein-rich interstitial fluid due to lymphatic system inefficiency. It can be primary (congenital) or secondary (acquired, commonly after surgery, radiation, infection, or trauma), and it is frequently chronic and progressive, particularly following cancer treatment.

Complete decongestive therapy (CDT), also referred to as complex lymphedema therapy (CLT), is the noninvasive, multimodal conservative standard of care intended to reduce swelling and restore function. CDT comprises skin and nail care, manual lymphatic drainage (MLD), multi-layer compression bandaging, therapeutic exercise, and patient education/maintenance.

Policy Summary

Payeramerican_specialty_health

PolicyComplex lymphedema therapy (Complete Decongestive Therapy)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMay 15, 2025

Next Review DateMay 15, 2026

Key ActionDocument limb volume measurements and prior conservative management when submitting claims; include appropriate covered diagnosis and procedure codes to avoid denial.

SourceLink

On This Page

Diagnosis and measurement support: Diagnosis and treatment decisions should be supported by documented limb volume or circumference measurements and staging; many guidelines recommend >10% limb volume difference to confirm lymphedema.>10%

Use validated instruments (BIS, water volumetry, tape, perometry) when available and document pre/post measurements.

Assessment and documentation: Decisions about CDT and adjunct interventions should be supported by documented staging and objective limb volume or circumference measurements; standardized measures are recommended.>10%

Record baseline and follow-up measurements to demonstrate clinical response; measurement instruments with reliability evidence include BIS, water volumetry, tape, and perometry.

Guideline supportRecommended by most guidelines and international consensus for confirming lymphedema diagnosis

inv-19: MLD / LLLT dose threshold associated with benefit — session counts and regimen notes

MLD dose associated with benefit≥20 sessions or treatment duration >2 weeks associated with significant volume reduction in some analyses

LLLT regimens notedRegimens >15 sessions and protocols such as 3×/week at 1.5–2 J/cm2 showed better swelling reduction in some studies

Evidence caveatPositive effects reported in subgroup analyses; overall evidence quality variable and further research needed

inv-20: Unit length — time reporting unit for therapy codes (per 15 minutes)

Unit length for therapy codesEach code reported per 15 minutes

Applies toHCPCS/CPT codes 97140 and S8950 as listed in policy

Billing implicationReport number of 15-minute units to reflect total therapy time provided

No explicit prior authorization procedures are specified in these policy sections.
Document limb volume measurements and prior failed conservative therapies to support medical necessity.

Prior Authorization

Intensive/adjunct CDT may need prior authorization

Prior authorization may be required when requesting intensive CDT programs or adjunctive devices/therapies (e.g., APCDs/advanced pneumatic devices) because such requests warrant documentation of diagnosis, staging and prior conservative management.

Intensive or adjunct interventions have variable evidence and often require supporting documentation.
Provide limb volume measurements, staging, and documentation of failed conservative care when requesting intensive or adjunct therapies.

Billing Rule

Coverage contingent on meeting policy criteria for 97140 and S8950

Coverage for HCPCS codes 97140 (manual therapy techniques including manual lymphatic drainage) and S8950 (complex lymphedema therapy) is conditional on meeting the policy’s clinical criteria; report each code in 15‑minute units.

Codes 97140 and S8950 are considered medically necessary when applicable policy criteria are met.
Report each unit per 15 minutes as specified in the Coding Information section.

Note

References do not define prior‑auth requirements

The References section does not specify prior authorization requirements; use cited literature to support medical necessity but follow the policy’s clinical documentation expectations.

References are provided for evidence but do not define operational prior authorization rules.
Ensure clinical documentation aligns with the policy when using literature to justify services.

Documentation Required

Document failed conservative management before CDT

Ensure documentation shows prior conservative management (home exercises, limb elevation, compression garments) failed before considering complex lymphedema therapy (CDT) as medically necessary.

Document prior unsuccessful therapies (elevation, bandaging, diuresis, etc.) in the medical record to justify skilled services.

Step Therapy

Document rationale when choosing IPC vs MLD (step therapy considerations)

Be aware that evidence shows some regimens (IPC plus bandaging) may be non‑inferior to regimens including MLD; document rationale when selecting IPC or MLD and include trial details (sessions, excess volume thresholds) if relevant.

Randomized trials reported non‑inferiority of IPC+bandages compared with trimodal therapy for stage II–III lymphedema.
When relying on IPC instead of MLD, include clinical justification and supporting trial parameters (e.g., 20 sessions, excess volume >10%).

Documentation Required

Conservative‑first: document CDT components and response

Follow a conservative‑first approach: CDT (MLD, compression bandaging/garments, skin care, exercise, education) is the mainstay of treatment and should be documented as delivered before escalation.

CDT is recognized internationally as the primary conservative care for lymphedema.
Document delivery of CDT components and patient response prior to requesting additional modalities.

Billing Rule

Code distinctions — covered vs not‑medically‑necessary

Differentiate billed codes: 97140 and S8950 are covered when criteria are met, while CPT 97016 (vasopneumatic devices) is listed as not medically necessary—no explicit step therapy sequence is defined.

Do not bill CPT 97016 for lymphedema therapy (considered not medically necessary).
The policy does not prescribe a stepwise sequence between covered codes.

Step Therapy

No formal step‑therapy mandates — document clinical justification

The policy excerpts do not impose formal step therapy requirements; when therapies are selected, document diagnosis, prior conservative care, and measurement evidence supporting the choice.

No step therapy mandates are specified in these sections.
Clinical justification and documentation remain necessary when requesting non‑standard or adjunctive therapies.

Documentation Required

Document diagnosis and exclude alternative etiologies

Support the diagnosis and medical necessity with documentation that rules out other causes of edema (chronic venous insufficiency, CHF, acute infection) and reports recent changes and prior unsuccessful therapies.

Report recent changes in condition and prior unsuccessful conservative treatments to justify skilled CDT.
Documentation must distinguish lymphedema from other etiologies.

Documentation Required

Record limb volume measurements (baseline and follow‑up)

Include limb volume measurements before, during, and after treatment in the record; guideline‑based diagnosis commonly uses a limb volume difference of >10% to confirm lymphedema.

Record objective limb volume or circumference measurements at baseline and follow‑up.
Use a >10% limb volume difference compared with the contralateral limb as a diagnostic reference where applicable.

Documentation Required

Provide integrated diagnostic assessment with volume threshold

Diagnostic documentation should integrate medical and psychological assessment, physical exam, and limb volume measurement (commonly >10% difference) to confirm lymphedema and justify therapy.

Provide integrated assessment including staging and objective volume data.
Document functional impairment attributable to lymphedema when claiming medical necessity.

Documentation Required

Use validated instruments for limb volume measurement

Use validated measurement instruments to document lymphedema: Bioelectrical Impedance Spectroscopy (BIS), water volumetry, tape measurement, or perometry are recommended methods with evidence of reliability.

BIS can detect alterations in extracellular fluid in stage 1 lymphedema; water volumetry, tape, and perometry detect volume changes starting in stage 2.
In research, water volumetry is indicated as a reference test for upper‑extremity lymphedema.

Denial Risk

Claims lacking covered codes may be denied

Claims billed for services without covered diagnosis or procedure code(s) listed in the Coding Information section (e.g., billing CPT 97016 for lymphedema) may be denied as not covered.

Ensure the most appropriate covered codes (97140, S8950) are used; CPT 97016 is listed as not medically necessary for lymphedema.
Claims lacking covered code(s) under this policy will be denied.

Denial Risk

Address evidence limitations in documentation

The policy notes that many trials have 'some concerns' or 'high risk of bias'; be prepared to address evidence limitations in documentation when clinical benefit is uncertain to avoid medical necessity challenges.

Documentation should include objective measures and rationale because low‑quality evidence may prompt coverage scrutiny.
Cite guideline‑based diagnosis and prior conservative management to support requests for therapy.

Spontaneously reversible; pitting edema, increase in limb girth; often responsive to conservative measures

Stage IISpontaneously irreversible; non-pitting edema with tissue fibrosis and increased limb girth

Stage IIILymphostatic elephantiasis; irreversible fibrotic changes, marked enlargement, skin changes (papillomas, hyperkeratosis)

inv-44: Phase I CDT — intensive phase description

Phase I (intensive) — durationUsually 2–4 weeks (typical CLT program) with frequent in-office visits

Core componentsSkin and nail care, manual lymphatic drainage (MLD) typically 30–60 minutes, multilayer compression bandaging, and therapeutic exercise

GoalAim to reduce lymphedema volume prior to transition to maintenance and self-management

inv-45: Phase II CDT — maintenance phase description

Phase II (maintenance) — focusSkin care and use of compression garments (low-stretch stocking or sleeve) to conserve treatment results

Self-managementEmphasis on patient education, home-based compression, self-MLD, and exercise to maintain gains from Phase I

TimingBegins after successful volume reduction in Phase I; ongoing long-term strategy to prevent recurrence

inv-46: Complete decongestive therapy (CDT) — combined conservative therapy definition

Combined conservative therapyCDT = manual lymphatic drainage + low-stretch multilayer compression bandaging + skin care + therapeutic exercise + patient education/maintenance

Clinical roleConsidered the gold standard conservative approach for lymphedema management

Outcome goalReduce/control swelling and restore limb function; enables transition to home-based maintenance

inv-47: Manual lymphatic drainage (MLD) — description and evidence summary for pain/volume outcomes

DescriptionSpecialized, light massage-like techniques intended to stimulate residual lymphatic vessels and promote lymph flow; typically performed 30–60 minutes

Evidence for painSystematic reviews/meta-analyses report MLD provides significant improvement in pain for BCRL patients

Evidence for volumeVolume reduction results are mixed; some analyses show benefit when treatment course ≥20 sessions or >2 weeks, but overall findings are inconsistent

inv-48: Bioelectrical Impedance Spectroscopy (BIS) — measurement instrument and use

InstrumentBioelectrical Impedance Spectroscopy (BIS)

Measurement roleDetects alterations in extracellular fluid and useful for identifying stage 1 (subclinical) lymphedema

Research noteIncluded among recommended reliable instruments alongside water volumetry, tape measurement and perometry

inv-49: Water volumetry / tape measurement / perometry — measurement instrument descriptions and roles

Water volumetryReference test in research for measuring upper-extremity lymphedema; detects volume alterations beginning around Stage II

Tape measurementCircumferential measures used to detect volume changes starting from Stage II; practical for clinical use

PerometryOptical/infrared limb volume assessment; reliable instrument for detecting stage-based volume alterations